Neptune Tech & Bioresource

NEPT-T

TSE:NEPT

4.06
0.18 (4.25%)
Neptune Wellness Solutions is a nutrition products company focused on the business of customized unique nutrition solutions, specialty ingredients and consumer brands.
More at Wikipedia

Analysis and Opinions about NEPT-T

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
February 2, 2016

(A Top Pick Dec 10/14. Down 26.57%.) Healthcare company. Has a lot of upside because they are developing a drug for treatment of hypertriglyceridemia. It should hopefully go into phase 3 trials by next year. Technically it is starting to outperform now. New CEO. A table pounder at this price.

Show full opinionHide full opinion

(A Top Pick Dec 10/14. Down 26.57%.) Healthcare company. Has a lot of upside because they are developing a drug for treatment of hypertriglyceridemia. It should hopefully go into phase 3 trials by next year. Technically it is starting to outperform now. New CEO. A table pounder at this price.

PAST TOP PICK
PAST TOP PICK
December 7, 2015

(Top Pick Dec 10/14, Down 25.12%) Their production plant blew up last year, but it was rebuilt and came back on line. However, there were hiccups. Now it is performing ahead of expectations. They are a leader in Omega 3 production. He was buying today.

Show full opinionHide full opinion

(Top Pick Dec 10/14, Down 25.12%) Their production plant blew up last year, but it was rebuilt and came back on line. However, there were hiccups. Now it is performing ahead of expectations. They are a leader in Omega 3 production. He was buying today.

PAST TOP PICK
PAST TOP PICK
September 21, 2015

(Top Pick Sep 10/14, Down 27.19%) He bought more today. It was beaten up because a plant blew up two or three years ago and they built a new one with insurance proceeds and now it is up and running. Over the next two quarters the market will see they are back to profitability.

Show full opinionHide full opinion

(Top Pick Sep 10/14, Down 27.19%) He bought more today. It was beaten up because a plant blew up two or three years ago and they built a new one with insurance proceeds and now it is up and running. Over the next two quarters the market will see they are back to profitability.

PAST TOP PICK
PAST TOP PICK
June 3, 2015

(A Top Pick June 16/14. Down 37.08%.) Very disappointing from a stock performance perspective, but from a corporate perspective there has been some very positive things happen. They are one year further along in the development of their potential revolutionary drug, Capri, where they are talking about phase 3 trial design. It should be launched hopefully by the end of the year into phase 3 trials. Also, have a new phenomenal CEO who will help get the company turned around. Recently took a bit of a hit because of problems starting their brand-new plant, but that should be turned around by the summer. This is a table pounder.

Show full opinionHide full opinion

(A Top Pick June 16/14. Down 37.08%.) Very disappointing from a stock performance perspective, but from a corporate perspective there has been some very positive things happen. They are one year further along in the development of their potential revolutionary drug, Capri, where they are talking about phase 3 trial design. It should be launched hopefully by the end of the year into phase 3 trials. Also, have a new phenomenal CEO who will help get the company turned around. Recently took a bit of a hit because of problems starting their brand-new plant, but that should be turned around by the summer. This is a table pounder.

TOP PICK
TOP PICK
April 7, 2015

His top pick for healthcare. Thinks this is a potential multi-bagger. Have almost $39 million of cash on their balance sheet. Just built a $30 million plant to produce Neptune Krill oil, which should be profitable this coming quarter. Also, own 50% of their pharmaceutical development subsidiary which has multimillion dollar potential. They produce Capri, a treatment for triglyceride uremia. Their phase 2 trials showed a 38% drop in triglycerides, which is 2X the drop that the current drug in the market has shown.

Show full opinionHide full opinion

His top pick for healthcare. Thinks this is a potential multi-bagger. Have almost $39 million of cash on their balance sheet. Just built a $30 million plant to produce Neptune Krill oil, which should be profitable this coming quarter. Also, own 50% of their pharmaceutical development subsidiary which has multimillion dollar potential. They produce Capri, a treatment for triglyceride uremia. Their phase 2 trials showed a 38% drop in triglycerides, which is 2X the drop that the current drug in the market has shown.

COMMENT
COMMENT
January 2, 2015

Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs.

Show full opinionHide full opinion

Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs.

TOP PICK
TOP PICK
December 10, 2014

Krill oil. They own half of Acasti Pharmaceutical (APO-X), so you have the upside from Acasti through Capri going into phase 3 trials this year. This company has great resources with the plant producing Neptune Krill oil, being sold through Natural stores, which has a beneficial health effect. 2 years ago their plant blew up in Sherbrooke Quebec. The plant just came on stream this year and will be profitable this month or next. If that starts generating cash flow, investors will start to recognize this. A new CEO will be able to start talking to investors and will be getting a bunch of new institutions involved. $150 million market, which he views as worth over $1 billion.

Show full opinionHide full opinion

Krill oil. They own half of Acasti Pharmaceutical (APO-X), so you have the upside from Acasti through Capri going into phase 3 trials this year. This company has great resources with the plant producing Neptune Krill oil, being sold through Natural stores, which has a beneficial health effect. 2 years ago their plant blew up in Sherbrooke Quebec. The plant just came on stream this year and will be profitable this month or next. If that starts generating cash flow, investors will start to recognize this. A new CEO will be able to start talking to investors and will be getting a bunch of new institutions involved. $150 million market, which he views as worth over $1 billion.

TOP PICK
TOP PICK
September 10, 2014

This is going to be one of the leaders of tomorrow. Probably one of the most exciting opportunities in the market today. They provide fossil lipids, primarily out of Antarctic krill, which has a great affect on your cardiovascular system. Very beneficial for cholesterol and triglycerides. In the next 3 weeks, their subsidiary Acasti Pharma, will be reporting a pivotal phase 2 trial, which he thinks will catalyze the stock and drive both companies up a lot in the market. A multi-bagger potential.

Show full opinionHide full opinion

This is going to be one of the leaders of tomorrow. Probably one of the most exciting opportunities in the market today. They provide fossil lipids, primarily out of Antarctic krill, which has a great affect on your cardiovascular system. Very beneficial for cholesterol and triglycerides. In the next 3 weeks, their subsidiary Acasti Pharma, will be reporting a pivotal phase 2 trial, which he thinks will catalyze the stock and drive both companies up a lot in the market. A multi-bagger potential.

DON'T BUY
DON'T BUY
June 20, 2014

He is Short this. It shows up poorly in his model. Doesn’t feel that people are going to pay a big premium for krill oil versus other types of omega-3’s.

Show full opinionHide full opinion

He is Short this. It shows up poorly in his model. Doesn’t feel that people are going to pay a big premium for krill oil versus other types of omega-3’s.

TOP PICK
TOP PICK
June 16, 2014

A company that has gone through a lot of issues over the last 2 years. After losing their manufacturing plant in Sherbrooke, their new plant has been rebuilt, and they are just in the process of getting the Québec government approvals to start manufacturing again. Has some blockbuster potential. Developing a new pharmaceutical through their subsidiary, called Capri, a treatment for cholesterol and triglycerides.

Show full opinionHide full opinion

A company that has gone through a lot of issues over the last 2 years. After losing their manufacturing plant in Sherbrooke, their new plant has been rebuilt, and they are just in the process of getting the Québec government approvals to start manufacturing again. Has some blockbuster potential. Developing a new pharmaceutical through their subsidiary, called Capri, a treatment for cholesterol and triglycerides.

DON'T BUY
DON'T BUY
April 21, 2014

Has been a bit of controversial type of stock. A krill oil and omega-3 manufacturer. The big downturn last year was because of a fire in their plant so they had to stop production completely. Believes that it is coming back online. He is not a big believer in the science that he has read on. Doesn’t believe people are willing to pay premium prices for krill oil and omega-3 versus regular omega-3.

Show full opinionHide full opinion

Has been a bit of controversial type of stock. A krill oil and omega-3 manufacturer. The big downturn last year was because of a fire in their plant so they had to stop production completely. Believes that it is coming back online. He is not a big believer in the science that he has read on. Doesn’t believe people are willing to pay premium prices for krill oil and omega-3 versus regular omega-3.

HOLD
HOLD
April 17, 2014

If this drops below $2.40, you want to get out. Use $2.40 as your Stop. Really not a lot of expectation.

Show full opinionHide full opinion

If this drops below $2.40, you want to get out. Use $2.40 as your Stop. Really not a lot of expectation.

WATCH
WATCH
March 24, 2014

A very important year for them. They own 50% of their subsidiary Acasti Pharma (APO-X), the developer of Capri, which is potentially a revolutionary treatment for cholesterol and hyper triglyceride. The big phase 2 trial results should be coming out sometime in the next 3-6 months. When those results come out they will either drive the stock up a huge amount, which is what he thinks will happen or it will drive it down. Stock has recently been under a bit of pressure. Raised some equity and haven’t made a real good pronouncement of their reason for it.

Show full opinionHide full opinion

A very important year for them. They own 50% of their subsidiary Acasti Pharma (APO-X), the developer of Capri, which is potentially a revolutionary treatment for cholesterol and hyper triglyceride. The big phase 2 trial results should be coming out sometime in the next 3-6 months. When those results come out they will either drive the stock up a huge amount, which is what he thinks will happen or it will drive it down. Stock has recently been under a bit of pressure. Raised some equity and haven’t made a real good pronouncement of their reason for it.

PAST TOP PICK
PAST TOP PICK
December 6, 2013

(A Top Pick Sept 4/13. Down 14.29%.) Would characterize this as the most exciting stock in his portfolio. Their majority owned subsidiary, Acasti Pharmaceuticals (APO-X) is developing a revolutionary cholesterol/glycerids treatment (CaPre) and have to finance to raise money for a phase 3 trial. Feels both companies are table pounding buys. Stocks have been beaten up on short-term concerns. Expects them both to double or triple in the next year.

Show full opinionHide full opinion

(A Top Pick Sept 4/13. Down 14.29%.) Would characterize this as the most exciting stock in his portfolio. Their majority owned subsidiary, Acasti Pharmaceuticals (APO-X) is developing a revolutionary cholesterol/glycerids treatment (CaPre) and have to finance to raise money for a phase 3 trial. Feels both companies are table pounding buys. Stocks have been beaten up on short-term concerns. Expects them both to double or triple in the next year.

PARTIAL SELL
PARTIAL SELL
October 24, 2013

The biotech sector in the US has been on fire. There aren’t too many Canadian biotechs and he is not sure if this would be classified as one. Not a huge fan of biotechs in general. If you own, consider exiting part of your position.

Show full opinionHide full opinion

The biotech sector in the US has been on fire. There aren’t too many Canadian biotechs and he is not sure if this would be classified as one. Not a huge fan of biotechs in general. If you own, consider exiting part of your position.

Showing 16 to 30 of 65 entries